|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
While the previously reported association between TNF*-238A and psoriasis seems to primarily reflect LD with PSORS1, TNF*-857T may represent a risk factor for PsA that is independent of the PSORS1 allele.
|
17530646 |
2007 |
|
Psoriasis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Gene expression changes in psoriasis lesions have been well documented, and strongly support an important role for tumor necrosis factor and interferon gamma signal pathways in its pathogenesis.
|
17093502 |
2007 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Anti-TNF therapy has achieved encouraging efficacy in both the joints and skin disease, improving function and quality of life and inhibiting radiological progression measured in patients with PsA and psoriasis.
|
17244977 |
2007 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
We found that the TNF-alpha-308A allele frequency was significantly decreased among patients with early-onset psoriasis in comparison with control subjects (7.5% vs. 15.4%, P = 0.022), whereas in the same patients the frequency of the TNF-alpha-238A allele was significantly increased as compared with the controls (16.8% vs. 3.1%, P = 0.000017, odds ratio 8.79, 95% confidence interval 2.606-29.678).
|
17553030 |
2007 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Identification of cellular pathways of "type 1," Th17 T cells, and TNF- and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine A in psoriasis.
|
18209089 |
2008 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Analysis of gene expression confirmed dysregulation in all expected functional categories, such as IFN signaling and keratinocyte differentiation, and allowed molecular fingerprinting of a previously characterized dendritic cell subset associated with psoriasis tumor necrosis factor alpha (TNF-alpha)- and inducible nitric oxide synthase (iNOS)-producing CD11b(INT) DC (Tip-DC).
|
17637826 |
2008 |
|
Psoriasis
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Activation of keratinocyte protein kinase C zeta in psoriasis plaques.
|
18385757 |
2008 |
|
Psoriasis
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
These findings establish the aberrant expression and distribution of NURR1 in psoriasis and suggest that clinical benefits of TNF-alpha inhibition may be mediated through altered NURR1 activity.
|
17671512 |
2008 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
LHGDN |
Although it has been documented that reactive oxygen species (ROS) are involved in TNF-alpha-induced signaling pathways associated with certain inflammatory diseases, their role in TNF-alpha signaling cascades has not been examined in primary human keratinocytes used as a model of inflammatory skin disease and psoriasis.
|
18463678 |
2008 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The following cytokines are directly involved in psoriasis: TNF, IL-1, IL-2, IL-6, IL-7, IL-8, IL-15, IL-18, IL-19, IL-20, IL-23 whereas IL-4, IL-10, IL-12 as well as IL-11, IL-17 and IFN-gamma are rather indirectly engaged.
|
18296259 |
2008 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
These genes represent potential therapeutic targets of TNF antagonists in psoriasis.
|
17928893 |
2008 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
To analyze globally the genomic effects of TNF inhibition in patients with psoriasis, and to compare genomic profiles of patients who responded or did not respond to treatment.
|
19895991 |
2009 |
|
Psoriasis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These findings validate TNF-alpha mRNA as a target molecule for a potential persistent RNA-based treatment of psoriasis and establish the use of small RNA effectors as a novel platform for target validation in psoriasis and other skin disorders.
|
19568223 |
2009 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Patients with psoriasis and psoriatic arthritis respond well to tumor necrosis factor alpha (TNFalpha) blockers in general; however, there is now mounting evidence that a small cohort of patients with rheumatoid arthritis who receive TNFalpha blockers develop psoriasis.
|
20112373 |
2010 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Inhibition of TNF-alpha, IL-12 and IL-23 production, as well as NK and keratinocyte responses by this phosphodiesterase-4 inhibitor suggests a novel approach to the treatment of psoriasis.
|
20050849 |
2010 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We performed a case-control study of 69 patients with psoriasis type I and 70 controls, characterized clinical progression along 10-years of follow-up in mild or severe disease and determined HLA class I, II, and TNF single nucleotide polymorphisms (SNPs) -238 and -308 polymorphisms to demonstrate whether these polymorphisms may be genetic risk for susceptibility to psoriasis or severity of the disease in Brazilians.
|
20931685 |
2010 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Investigations into the genetics of psoriasis has spurred further examinations into the contributions of immune mediators such as IL-23, IL-17, IL-22, and TNF as well as cellular mediators including a variety of dendritic cell populations of the skin and the growing number of T cell types, including the Th17 and Th22 subsets.
|
21317854 |
2011 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
TNF is critically involved in the pathogenesis of psoriasis.
|
21672030 |
2011 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our data predict that psoriasis therapy with either TNF or IL-17 antagonists will produce greater modulation of the synergistic/additive gene set, which consists of the most highly expressed genes in psoriasis skin lesions.
|
21085185 |
2011 |
|
Psoriasis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The detrimental activity of TNF can be blocked by various antagonists, and commercial therapeutics based upon this principle have been approved for treatment of diseases including rheumatoid arthritis, Crohn's disease and psoriasis.
|
20444206 |
2011 |
|
Psoriasis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our current study suggests that TNF inhibits barrier protein expression, and TNF-α antagonists may contribute to clinical improvement in patients with psoriasis by improving barrier protein expression.
|
21346775 |
2011 |
|
Psoriasis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
IL-1α, IL-6 and TNF-α expression levels were higher in patients with psoriasis.
|
21574971 |
2011 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In this study, we report association of response of psoriasis to TNF blockers with two TNFAIP3 single-nucleotide polymorphisms (rs2230926 in exon 7 and rs610604 in intron 3) and their haplotypes.
|
22113471 |
2012 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
A Greek multicenter collaboration was established to recruit a cohort of patients (n = 80) with psoriasis treated with anti-TNF drugs.
|
22111980 |
2012 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
To examine whether the G or the C allele, at position -174 in the promoter of IL-6, influences the relationships between body weight, body composition, and therapeutic response to TNF-α blockers in psoriasis.
|
22158445 |
2012 |